# EDGAR Filing Document

**Accession Number:** 0001854270
**File Stem:** 0001854270-25-000077
**Filing Date:** 2025-7
**Character Count:** 18460
**Document Hash:** 0b388726216bbdc3c66cf9800cc08ca7
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001854270-25-000077.hdr.sgml**: 20250718

**ACCESSION NUMBER**: 0001854270-25-000077

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20250718

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250718

**DATE AS OF CHANGE**: 20250718

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Senti Biosciences, Inc.
- **CENTRAL INDEX KEY:** 0001854270
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 862437900
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40440
- **FILM NUMBER:** 251132695

**BUSINESS ADDRESS:**
- **STREET 1:** 2 CORPORATE DRIVE, FIRST FLOOR
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080
- **BUSINESS PHONE:** (650) 239-2030

**MAIL ADDRESS:**
- **STREET 1:** 2 CORPORATE DRIVE, FIRST FLOOR
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Senti Biosciences, Inc.\
- **DATE OF NAME CHANGE:** 20220615

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Dynamics Special Purpose Corp.
- **DATE OF NAME CHANGE:** 20210331

?xml version='1.0' encoding='ASCII'? snti-20250718

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

___________________________________

**FORM 8-K**

___________________________________

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): July 18, 2025**

___________________________________

**SENTI BIOSCIENCES, INC.**

**(Exact name of Registrant as specified in its charter)**

___________________________________

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-40440** | **86-2437900** |
| **(State or other jurisdiction**<br>**of incorporation)** | **(Commission**<br>**File Number)** | **(IRS Employer**<br>**Identification No.)** |

---

**2 Corporate Drive, First Floor**

**South San Francisco, California 94080**

**(Address of principal executive offices including zip code)**

**Registrant's telephone number, including area code: (650) 239-2030**

**(Former name or former address, if changed since last report)**

___________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading**<br>**Symbol** | **Name of each exchange**<br>**on which registered** |
| **Common Stock, par value $0.0001 per share** | **SNTI** | **The Nasdaq Capital Market** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

------

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

*Appointment of Director*

Mr. Baum, age 36, is a serial entrepreneur who has founded and sold multiple companies including Blue Vision Labs, a localization and mapping software company for self-driving cars (sold to Lyft in 2018); Operam, a data analytics and marketing insights company; and Represent.com, an e-commerce platform (sold to CustomInk in 2016). Mr. Baum has been an angel investor for over a decade and has personally made over 200 investments in companies such as Uber, Airbnb, Slack, Flexport, Carta, PillPack, and Sweetgreen. He is currently a Managing Partner of K5 Global, a venture capital firm he co-founded in January 2020. Mr. Baum studied Game Theory at Swarthmore College and Oxford University. The Company believes Mr. Baum is qualified to serve on the Board because of his financial and investment management expertise.

Mr. Baum will be compensated for his service as a non-employee director in accordance with the Company's Amended and Restated Non-Employee Director Compensation Policy, as more fully described in the Company's Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on April 30, 2025. In accordance with those arrangements, Mr. Baum was granted an initial option award to purchase 43,900 shares of the Company's common stock, par value $0.0001 per share (the "Common Stock"), pursuant to the Company's Amended and Restated 2022 Equity Incentive Plan (the "A&R Plan"), which will vest in equal monthly installments over three years from its grant date, subject to Mr. Baum's continued service on the Board; provided, that upon a Change of Control (as defined in the A&R Plan), all shares of Common Stock subject to the option shall become fully vested and exercisable, provided, further, however, that all vesting shall cease if Mr. Baum resigns from the Board or otherwise ceases to serve as a director of the Company, unless the Company and Mr. Baum have entered into a written agreement for Mr. Baum to provide uninterrupted services to the Company in a capacity other than as a director at such time or prior to such time Mr. Baum resigns from or ceases to serve as a director, and such written agreement expressly states that such services constitute Continuous Service (as defined in the A&R Plan), in which case, all vesting shall cease upon termination of the Continuous Service. As a non-employee director, Mr. Baum will also be eligible to receive an annual stock option grant to purchase 21,950 shares of Common Stock, as well as annual cash retainers of $35,000 for serving as a member of the Board.

Mr. Baum has no family relationship with any of the executive officers or directors of the Company. Mr. Baum is not a party to any transaction with the Company that would require disclosure under Item 404(a) of Regulation S-K, and, except as described above, there are no arrangements or understandings between Mr. Baum and any other persons pursuant to which he was selected as director.

In connection with Mr. Baum's election to the Board, Mr. Baum will enter into the Company's standard form of indemnification agreement, a copy of which was filed as Exhibit 10.5 to the Company's Registration Statement on Form S-4, as amended (File No. 333- 262707) filed with the Securities and Exchange Commission on May 10, 2022. Pursuant to the terms of the indemnification agreement, the Company may be required, among other things, to indemnify Mr. Baum for certain expenses, including attorneys' fees, judgments, fines, penalties, excise taxes and settlement amounts actually and reasonably incurred by him in any action or proceeding arising out of his service as one of the Company's directors.

**Item 7.01 Regulation FD Disclosure.**

On July 18, 2025, the Company issued a press release announcing the appointment of Mr. Baum to the Board. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.

This information in this Item 7.01 of this Current Report on Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that

------

Section, or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 99.1 | <u>[Press Release, dated July 18, 2025](ex991snti2025newbodmember2.htm)</u> |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
| | | **SENTI BIOSCIENCES, INC.** | **SENTI BIOSCIENCES, INC.** |
| Date: | July 18, 2025 | By: | /s/ Timothy Lu |
|  |  | Name: | Timothy Lu, M.D., Ph.D. |
|  |  | Title: | Chief Executive Officer |

---

## Exhibit 99.1

![sentijpeg.jpg](sentijpeg.jpg)

**Exhibit 99.1**

**Senti Bio Appoints Entrepreneurial Leader and Investor, Bryan Baum, to Board of Directors** 

**SOUTH SAN FRANCISCO, Calif., July 18, 2025** (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) ("Senti Bio" or the "Company"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that it has appointed Bryan Baum to its Board of Directors.

Mr. Baum is a serial entrepreneur and investor and is the Co-Founder and Managing Partner of K5 Global. His portfolio includes category-defining companies such as SpaceX, xAI, Anduril, Canva, Databricks, Grafana, OpenAI, and others. He has also founded and successfully exited multiple ventures.

Timothy Lu, M.D., Ph.D. Senti Bio's Co-Founder and Chief Executive Officer commented, "We are pleased to welcome Bryan to our Board of Directors. His keen insight and successful track record have equipped him with invaluable expertise on investing in and scaling successful companies that we believe will be a key asset to Senti as we continue to advance our programs. We look forward to leveraging his leadership and skillset to help propel Senti to fully realize the potential of our Gene Circuits."

Mr. Baum added, "Senti's engineering of Logic Gated cell therapies represents an exciting frontier with the potential to transform treatments for cancer indications not addressable by existing drugs. I am excited to work closely with the team to help execute on the development path forward and optimize value in the near and long term for all stakeholders."

Mr. Baum also started 818 Tequila and previously founded and sold multiple companies including Parrot a legal tech company using AI to accelerate workflows and depositions(sold to Filevine in 2025), Blue Vision Labs, a localization and mapping software company for self-driving cars (sold to Lyft in 2018); Operam, a data analytics and marketing insights company; and Represent.com, an e-commerce platform (sold to CustomInk in 2016). Mr. Baum has been an angel investor for over a decade and has personally made over 200 investments in companies such as Uber, Airbnb, Slack, Flexport, Carta, PillPack, and Sweetgreen.

Bryan was named a Technology Pioneer by the World Economic Forum, featured in Forbes 30 under 30, and is on the board of the Federal Drug Agents Foundation. Bryan studied Game Theory at Swarthmore College and Oxford University and was an adjunct professor at the University of Southern California.

**About Senti Bio**

Senti Bio is a biotechnology company developing a new generation of cell and gene therapies for patients living with incurable diseases. To achieve this, Senti Bio is leveraging its synthetic biology platform to engineer Gene Circuits into new medicines with enhanced precision and control. These Gene Circuits are designed to precisely kill cancer cells, to spare healthy cells, to increase specificity to target tissues, and/or to be controllable even after administration. The Company's wholly-owned pipeline is comprised of cell therapies engineered with Gene Circuits

------

to target challenging liquid and solid tumor indications. Senti's Gene Circuits have been shown preclinically to work in both NK and T cells. Senti Bio has also preclinically demonstrated the potential breadth of Gene Circuits in other modalities and diseases outside of oncology, and continues to advance these capabilities through partnerships.

**Forward-Looking Statements**

This press release and document contain certain statements that are not historical facts and are considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements generally are identified by the words "believe," "could," "predict," "continue," "ongoing," "project," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," "forecast," "seek," "target" and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Forward-looking statements are predictions, projections, and other statements about future events that are based on current expectations of Senti Bio's management and assumptions, whether or not identified in this document, and, as a result, are subject to risks and uncertainties. Forward-looking statements include, but are not limited to, expectations regarding Senti Bio's progress future results. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on by any investor as, a guarantee, an assurance, a prediction, or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Senti Bio. Many factors could cause actual future results to differ materially from the forward-looking statements in this document, including but not limited to: (i) changes in domestic and foreign business, market, financial, political and legal conditions, (ii) changes in the competitive and highly regulated industries in which Senti Bio operates, variations in operating performance across competitors, changes in laws and regulations affecting Senti Bio's business, (iii) the ability to implement business plans, forecasts and other expectations, (iv) the risk of downturns and a changing regulatory landscape in Senti Bio's highly competitive industry, (v) risks relating to the uncertainty of any projected financial information with respect to Senti Bio, (vi) risks related to uncertainty in the timing or results of Senti Bio's clinical trial start up, clinical studies, patient enrollment, and GMP manufacturing startup activities, (vii) Senti Bio's dependence on third parties in connection with clinical trial startup, clinical studies, and GMP manufacturing activities, (viii) risks related to delays and other impacts from macroeconomic and geopolitical events, increasing rates of inflation and rising interest rates on business operations, (ix) risks related to the timing and utilization of the grant from CIRM, and (x) the success of any future research and development efforts by Senti Bio. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the "Risk Factors" section of Senti Bio's most recent periodic report filed with the U.S. Securities and Exchange Commission ("SEC"), and other documents filed by Senti Bio from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements in this document. There may be additional risks that Senti Bio does not

------

presently know, or that Senti Bio currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements in this document. Forward-looking statements speak only as of the date they are made. Senti Bio anticipates that subsequent events and developments may cause Senti Bio's assessments to change. Except as required by law, Senti Bio assumes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events, or otherwise.

**Availability of Other Information About Senti Biosciences, Inc.**

For more information, please visit the Senti Bio website at www.sentibio.com or follow Senti Bio on X (@SentiBio) (<u>https://x.com/sentibio</u>) and LinkedIn (Senti Biosciences) (<u>https://www.linkedin.com/company/senti-biosciences</u>). Investors and others should note that we communicate with our investors and the public using our company website (www.sentibio.com), including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on X (<u>https://x.com/sentibio</u>) and LinkedIn (<u>https://www.linkedin.com/company/senti-biosciences</u>). The information that we post on our website or on X (<u>https://x.com/sentibio</u>) or LinkedIn (<u>https://www.linkedin.com/company/senti-biosciences</u>) could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.

**Investor Contact:** 

JTC Team, LLC

Jenene Thomas

(908) 824-0775

SNTI@jtcir.com

<br>